Friday, July 04, 2025 11:09:10 AM
Here is quick summary from AI
So I don’t know what do you want FDA , you want FDA to do something they don’t do , and that too for a small , practically unknown company on an OTC , before company agrees to submit a formal application :
,
“🔹 The FDA does not “approve” a Statistical Analysis Plan (SAP) in the sense of issuing a formal approval letter like it does for a drug or device marketing application. Instead:
✅ FDA reviews and accepts the SAP as part of the overall trial protocol during the Investigational New Drug (IND) or Biologics License Application (BLA) process.
✅ The SAP becomes a binding part of the trial protocol that sponsors must follow once agreed with the FDA.
✅ If the SAP is modified after initial agreement, significant changes may require protocol amendments, which the FDA must again review and accept.
?
🚫 But the FDA does not grant an “SAP approval” certificate or decision. There’s no official “stamp of approval” issued specifically for the SAP alone.
?
🔎 What happens in practice:
• Sponsors typically submit their SAP as part of their trial protocol or as a separate document during the IND phase.
• The FDA may provide comments, request clarifications, or recommend changes.
• Once the sponsor addresses these, the FDA’s acceptance effectively indicates that the plan is adequate for evaluating trial data, but not formally “approved.”
?
📌 Key takeaway:
The FDA’s role is to accept an SAP as adequate for the trial’s intended endpoints, but it does not approve SAPs as standalone regulatory actions.”
So I don’t know what do you want FDA , you want FDA to do something they don’t do , and that too for a small , practically unknown company on an OTC , before company agrees to submit a formal application :
,
“🔹 The FDA does not “approve” a Statistical Analysis Plan (SAP) in the sense of issuing a formal approval letter like it does for a drug or device marketing application. Instead:
✅ FDA reviews and accepts the SAP as part of the overall trial protocol during the Investigational New Drug (IND) or Biologics License Application (BLA) process.
✅ The SAP becomes a binding part of the trial protocol that sponsors must follow once agreed with the FDA.
✅ If the SAP is modified after initial agreement, significant changes may require protocol amendments, which the FDA must again review and accept.
?
🚫 But the FDA does not grant an “SAP approval” certificate or decision. There’s no official “stamp of approval” issued specifically for the SAP alone.
?
🔎 What happens in practice:
• Sponsors typically submit their SAP as part of their trial protocol or as a separate document during the IND phase.
• The FDA may provide comments, request clarifications, or recommend changes.
• Once the sponsor addresses these, the FDA’s acceptance effectively indicates that the plan is adequate for evaluating trial data, but not formally “approved.”
?
📌 Key takeaway:
The FDA’s role is to accept an SAP as adequate for the trial’s intended endpoints, but it does not approve SAPs as standalone regulatory actions.”
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
